Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk

ScienceDaily·May 21

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research suggests that GLP-1 weight-loss drugs, such as Ozempic, may reduce the risk of heart attack and stroke. Stopping the use of these drugs may increase the risk of heart attack, stroke, and death. Additionally, the prices of these drugs, including Ozempic and Wegovy, are expected to decrease significantly due to recent announcements from drugmakers and the White House.

Full coverage

Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says

CNBC·Mar 18

Study Of 91,000 Patients Finds Ozempic-Class Drugs Slash Heart Attack Risk By 14%

StudyFinds·Jun 29

Ozempic-style drugs could slash complication risks after heart attacks, research suggests

Fox News·Mar 5

Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

CNBC·Nov 6

View original report at ScienceDaily ↗

Fetching the latest headlines…

Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk

Full coverage

Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says

Study Of 91,000 Patients Finds Ozempic-Class Drugs Slash Heart Attack Risk By 14%

Ozempic-style drugs could slash complication risks after heart attacks, research suggests

Trump Announces Major Price Cut for Ozempic, Wegovy and Similar Drugs

Wegovy, Ozempic Will Cost 50% Less in 2027 as Novo Nordisk Slashes Prices

Drugmaker cuts prices for Ozempic, Wegovy. Here's how much you will pay.

Cost of GLP-1 Drugs Plummets Under New White House Deal

Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage